The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse

被引：2
|
作者：
Agrawal, Vaibhav [1 ,2 ]
Salhotra, Amandeep [1 ,2 ]
Song, Joo [3 ]
Gu, Zhaohui [3 ,4 ]
Stein, Anthony S. [1 ,2 ]
Marcucci, Guido [1 ,2 ]
Forman, Stephen J. [1 ,2 ]
Pullarkat, Vinod [1 ,2 ]
Aldoss, Ibrahim [1 ,2 ,5 ]
机构：
[1] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA
[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA USA
[3] Beckman Res Inst City Hope, Dept Computat & Quantitat Med, Duarte, CA USA
[4] Beckman Res Inst City Hope, Dept Syst Biol, Duarte, CA USA
[5] City Hope Natl Med Ctr, Gehr Family Ctr Leukemia Res, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷 / 02期
关键词：
BLINATUMOMAB; RESISTANCE;
D O I：
10.1002/ajh.26787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E38 / E40
页数：3
相关论文
共 50 条
  • [41] Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
    Dourthe, Marie-Emilie
    Rabian, Florence
    Yakouben, Karima
    Chevillon, Florian
    Cabannes-Hamy, Aurelie
    Mechinaud, Francoise
    Grain, Audrey
    Chaillou, Delphine
    Rahal, Ilhem
    Caillat-Zucman, Sophie
    Lesprit, Emmanuelle
    Naudin, Jerome
    Roupret-Serzec, Julie
    Parquet, Nathalie
    Brignier, Anne
    Guerin-El Khourouj, Valerie
    Lainey, Elodie
    Caye-Eude, Aurelie
    Cave, Helene
    Clappier, Emmanuelle
    Mathis, Stephanie
    Azoulay, Elie
    Dallel, Jean Hugues
    Dhedin, Nathalie
    Madelaine, Isabelle
    Larghero, Jerome
    Boissel, Nicolas
    Baruchel, Andre
    LEUKEMIA, 2021, 35 (12) : 3383 - 3393
  • [42] Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
    Marie-Emilie Dourthe
    Florence Rabian
    Karima Yakouben
    Florian Chevillon
    Aurélie Cabannes-Hamy
    Françoise Méchinaud
    Audrey Grain
    Delphine Chaillou
    Ilhem Rahal
    Sophie Caillat-Zucman
    Emmanuelle Lesprit
    Jérôme Naudin
    Julie Roupret-Serzec
    Nathalie Parquet
    Anne Brignier
    Valérie Guérin-El Khourouj
    Elodie Lainey
    Aurélie Caye-Eude
    Hélène Cavé
    Emmanuelle Clappier
    Stéphanie Mathis
    Elie Azoulay
    Jean Hugues Dalle
    Nathalie Dhédin
    Isabelle Madelaine
    Jérôme Larghero
    Nicolas Boissel
    André Baruchel
    Leukemia, 2021, 35 : 3383 - 3393
  • [43] SAFETY AND EFFICACY COMPARISON OF HUMANIZED CD19 CAR-T VERSUS BLINATUMOMAB THERAPY FOR RELAPSED/REFRACTORY B-ALL PATIENTS
    Wang, Kexin
    Jiang, Songfu
    Hu, Yongxian
    Huang, He
    BONE MARROW TRANSPLANTATION, 2024, 59 : 199 - 200
  • [44] CD19-specific CAR-T cell therapy for relapsed/refractory non-B-cell acute leukaemia with CD19 antigen expression
    Liu, Shuangyou
    Yin, Zhichao
    Yu, Xinjian
    Zhao, Yongqiang
    Pan, Jing
    Song, Yanzhi
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 1 - 4
  • [45] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Iqbal, Madiha
    Jagadeesh, Deepa
    Chavez, Julio
    Khurana, Arushi
    Rosenthal, Allison
    Craver, Emily
    Epperla, Narendranath
    Li, Zhuo
    Isufi, Iris
    Awan, Farrukh T.
    Dholaria, Bhagirathbhai R.
    Maakaron, Joseph E.
    Sandoval-Sus, Jose D.
    Mishra, Rahul
    Saha, Aditi
    Annunzio, Kaitlin
    Bhaskar, Shakthi T.
    Sumransub, Nuttavut
    Fijalka, Andrew
    Ivanov, Stanislav A.
    Lin, Yi
    Kharfan-Dabaja, Mohamed A.
    BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 211 - 216
  • [46] CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
    Fry, Terry J.
    Shah, Nirali N.
    Orentas, Rimas J.
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Ramakrishna, Sneha
    Wolters, Pamela
    Martin, Staci
    Delbrook, Cindy
    Yates, Bonnie
    Shalabi, Haneen
    Fountaine, Thomas J.
    Shern, Jack F.
    Majzner, Robbie G.
    Stroncek, David F.
    Sabatino, Marianna
    Feng, Yang
    Dimitrov, Dimiter S.
    Zhang, Ling
    Sang Nguyen
    Qin, Haiying
    Dropulic, Boro
    Lee, Daniel W.
    Mackall, Crystal L.
    NATURE MEDICINE, 2018, 24 (01) : 20 - +
  • [47] Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
    Madiha Iqbal
    Deepa Jagadeesh
    Julio Chavez
    Arushi Khurana
    Allison Rosenthal
    Emily Craver
    Narendranath Epperla
    Zhuo Li
    Iris Isufi
    Farrukh T. Awan
    Bhagirathbhai R. Dholaria
    Joseph E. Maakaron
    Jose D. Sandoval-Sus
    Rahul Mishra
    Aditi Saha
    Kaitlin Annunzio
    Shakthi T. Bhaskar
    Nuttavut Sumransub
    Andrew Fijalka
    Stanislav A. Ivanov
    Yi Lin
    Mohamed A. Kharfan-Dabaja
    Bone Marrow Transplantation, 2024, 59 : 211 - 216
  • [48] Prior CD19-Targeted Therapy is Associated with Increased Non-Response and Relapse after CAR T Cell Therapy
    Pillai, V.
    Muralidharan, K.
    Rosenthal, J.
    Wertheim, G.
    Paessler, M.
    Maude, S.
    Grupp, S.
    Rheingold, S.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S54 - S55
  • [49] NK-cell trogocytosis of CD19 antigen: a rare B-ALL MRD mimicker
    Panda, Devasis
    Pathak, Amardeep
    Tejwani, Narender
    Mehta, Anurag
    BLOOD RESEARCH, 2022, 57 (04) : 249 - 249
  • [50] Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
    Pennell, Christopher A.
    Barnum, Jessie L.
    McDonald-Hyman, Cameron S.
    Panoskaltsis-Mortari, Angela
    Riddle, Megan J.
    Xiong, Zhengming
    Loschi, Michael
    Thangavelu, Govindarajan
    Campbell, Heather M.
    Storlie, Meghan D.
    Refaeli, Yosef
    Furlan, Scott N.
    Jensen, Michael C.
    Kean, Leslie S.
    Miller, Jeffrey S.
    Tolar, Jakub
    Osborn, Mark J.
    Blazar, Bruce R.
    MOLECULAR THERAPY, 2018, 26 (06) : 1423 - 1434
12345